Once bitten, no longer shy – Stryker turning back to biologics?
This article was originally published in Clinica
Executive Summary
Could orthopedic firm Stryker be looking to expand its presence in the regenerative medicine field, even though it had been burnt several years ago by the failure of its OP-1 products?